NDA 213871 · Pfizer
Cibinqo
Abrocitinib · Oral · Janus Kinase Inhibitor
NovelBreakthrough therapyPriority reviewCDER novel approval, Jan 14, 2022: To treat refractory, moderate-to-severe atopic dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jan 14, 2022
Approved uses
3
Original approval plus efficacy supplements
Registered trials
44
11 Phase 3, 9 recruiting
FAERS reports
3,948
1,377 serious, 70 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning. • Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Discontinue treatment with CIBINQO if serious or opportunistic infection occurs. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test. ( 5.1 ) • Higher rate of all-cause mortality, including sudden cardiovascular death, with another JAK inhibitor vs. TNF blockers in rheumatoid arthritis (RA) patients. CIBINQO is not approved for use in RA...
What it is approved for
From the label in effect Oct 15, 2026.
CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants. CIBINQO is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. ( 1 ) Limitation of Use : CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
Mechanism: CIBINQO is a Janus kinase (JAK) inhibitor. Abrocitinib reversibly inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site. In a cell-free isolated enzyme assay, abrocitinib was selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and tyrosine kinase (TYK) 2 (43-fold), as well as the broader kinome. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known. Both the parent compound and the active metabolites inhibit JAK1 activity in vitro with similar levels of selectivity.
Therapeutic areas: Oncology · Immunology and inflammation · Dermatology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 14, 2023 Supplement 4 · Efficacy LabelLetter
- Feb 9, 2023 Supplement 1 · Efficacy · priority review LabelLetter
- Jan 14, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLetterLabelReview
3 products under this application
- CIBINQO · ABROCITINIB 200MG · TABLET, ORAL · Prescription
- CIBINQO · ABROCITINIB 50MG · TABLET, ORAL · Prescription
- CIBINQO · ABROCITINIB 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Abrocitinib" as an intervention, any sponsor and status, largest first.
- Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03422822 · 3,166 participants · Start Mar 8, 2018 · Primary completion Dec 22, 2025
Drug: Abrocitinib 100 mg; Abrocitinib 200 mg and 4 more · For: Dermatitis, Atopic
Sites: Birmingham, Alabama; Anaheim, California; Encinitas, California · 539 sites in all
- Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03627767 · 1,235 participants · Start Jun 11, 2018 · Primary completion Sep 2, 2020
Drug: PF-04965842 100 mg; PF-04965842 200 mg and 1 more · For: Dermatitis; Dermatitis, Atopic; Eczema and 7 more
Sites: Birmingham, Alabama; Fountain Valley, California; Fremont, California · 235 sites in all
- Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03720470 · 838 participants · Start Oct 29, 2018 · Primary completion Dec 27, 2019
Drug: PF-04965842 100 mg; PF-04965842 200 mg and 3 more · For: Dermatitis; Dermatitis, Atopic; Eczema and 7 more
Sites: Birmingham, Alabama; Huntington Beach, California; Laguna Hills, California · 216 sites in all
- Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical TherapyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04345367 · 727 participants · Start Jun 11, 2020 · Primary completion Jul 13, 2021
Drug: Abrocitinib 200 mg · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Fountain Valley, California · 151 sites in all
- A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06807281 · 450 participants (planned) · Start Dec 2, 2025 · Primary completion Feb 22, 2032
Drug: Abrocitinib · For: Atopic Dermatitis
Sites: Birmingham, Alabama; North Little Rock, Arkansas; San Diego, California · 40 sites in all
- Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03575871 · 391 participants · Start Jun 29, 2018 · Primary completion Aug 13, 2019
Drug: PF-04965842 100 mg; PF-04965842 200 mg and 1 more · For: Dermatitis, Atopic
Sites: Anaheim, California; Los Alamitos, California; Rolling Hills Estates, California · 115 sites in all
- Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03349060 · 387 participants · Start Dec 7, 2017 · Primary completion Mar 26, 2019
Drug: PF-04965842 100 mg; PF-04965842 200 mg and 1 more · For: Dermatitis, Atopic
Sites: Birmingham, Alabama; Encinitas, California; San Diego, California · 88 sites in all
- JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic DermatitisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03796676 · 287 participants · Start Feb 18, 2019 · Primary completion Apr 8, 2020
Drug: Placebo; PF-04965842 and 1 more · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Madera, California; Mission Viejo, California · 136 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective537
- condition aggravated366
- off label use323
- pruritus247
- therapeutic product effect incomplete208
- rash184
- dermatitis atopic179
- nausea166
- headache109
- eczema95
- acne89
- fatigue83
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 11 |
| 2022 | 416 |
| 2023 | 1,084 |
| 2024 | 1,189 |
| 2025 | 967 |
| 2026 | 277 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cibinqo (Abrocitinib)
2024 spending
$17.1M
Beneficiaries
536
2,728 claims
Per beneficiary
$31,818
$183.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,849,145 |
| 2023 | $9,784,290 |
| 2024 | $17,054,378 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL, Wong MM, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Network Meta-Analysis
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update.
Drucker AM, Lam M, Prieto-Merino D, et al. · JAMA Dermatol 2024 · Systematic Review, Network Meta-Analysis
- Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Edwards SJ, Karner C, Jhita T, et al. · Health Technol Assess 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial.
Li H, Cheng H, Lu Q, et al. · Chin Med J (Engl) 2024 · Clinical Trial, Phase III, Letter
- The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
Yoon S, Kim K, Shin K, et al. · J Eur Acad Dermatol Venereol 2024 · Meta-Analysis, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.